Sarepta talks eteplirsen, fields questions

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT) provides updates and color regarding eteplirsen on what seems to have been a generally well-received Q2 conference call.

Investors should expect 96-week data in October.

NDA is still expected for H1 2014.

FDA will look at the totality of the data and could grant full approval (versus accelerated approval) based on robust clinical outcomes.

Manufacturing scale up is proceeding — the company should be ready for commercial launch by the end of 2014. (webcast)